AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it has executed a definitive agreement with the Department of Justice (DOJ) and the Office of Inspector General of the Department of Health and Human Services to resolve the issues raised in the DOJ’s investigation and the related qui tam complaint regarding the marketing of the Company’s surgical ablation devices.
The terms of the agreement are substantially identical to those previously disclosed and specifically state that AtriCure and its employees admit no wrongdoing or illegal activity. The qui tam complaint will be formally dismissed when the court approves the submission of the settlement papers and the notice of dismissal that has been prepared by the DOJ.
“Moving forward, the men and women of AtriCure have never been more passionate and committed to our mission of improving and preserving human life or more confident in the power of our strategic plan. We believe strongly that AtriCure is uniquely positioned to deliver results for patients, physicians and shareholders.”
David J. Drachman, President and Chief Executive Officer said, “Moving forward, the men and women of AtriCure have never been more passionate and committed to our mission of improving and preserving human life or more confident in the power of our strategic plan. We believe strongly that AtriCure is uniquely positioned to deliver results for patients, physicians and shareholders.”
CDC reports on its Mpox response